Product Details
Product Name:
Pramiconazole |
CAS No.:
219923-85-0 |
Purity:
98.84% |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | Pramiconazole |
Description | Pramiconazole (R126638) is an orally available antifungal compound.Pramiconazole is a candidate for the treatment of dermatophytes and cutaneous yeast infections in seborrheic dermatitis. |
In vivo | This study was performed in 2 groups of subjects suffering from seborrheic dermatitis. The first group (n = 17) remained untreated and was used as a control. Clinical, mycological, and metrological assessments were performed at inclusion and during the following 2 weeks. The second group of subjects (n = 10) received a single 200-mg oral dose of pramiconazole at inclusion. Clinical, mycological, and bio-metrological evaluations were performed before and during 1 month following the single antifungal intake. For both parts of the study, several parameters were assessed including yeast density, desquamation, erythema, itching, and sebum excretion. Results: In the control group, no significant changes were observed in any of the parameters during the observation period. The findings were markedly different in the pramiconazole-treated subjects. The yeast density was significantly improved on days 3, 7, and 28. Desquamation, erythema, itching, and the global clinical evaluation as assessed by the patients and investigators significantly improved on days 7 and 28. A trend in the decrease of scaliness was noted. No effect on sebum excretion was evidenced. In conclusion, a single 200-mg dose of pramiconazole exhibits in vivo efficacy in controlling some important clinical aspects of seborrheic dermatitis. Following a reduction in the number of yeasts on day 3, a decrease in the severity of clinical signs and symptoms occurred from day 7 onwards. Sebum excretion appeared uninvolved in the clearing process of seborrheic dermatitis. A single 200-mg dose of pramiconazole appears to abate seborrheic dermatitis. The density in Malassezia present on lesional skin is first decreased, followed by clearing of the clinical signs.[3] |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 6.25 mg/mL (9.47 mM), Sonication is recommended.
|
Keywords | Pramiconazole |
Inhibitors Related | Dehydroacetic acid sodium | 2-Butyl-1,2-benzisothiazolin-3-one | Tebuconazole | Veratraldehyde | Paclobutrazol | Lauryl betaine | Ammonium Chloride | Potassium sorbate | Geraniol | Sorbic acid |
Related Compound Libraries | Bioactive Compound Library | Anti-Fungal Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:7019-85-4
$1180.00 / 1mg
-
CAS:1169755-45-6
$55.00 / 5mg
-
CAS:554403-49-5
$127.00 / 1mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |